Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.67 +5.21%
EPS Growth %: -138.7%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
SFBC, KSBI, PVBK, More
EPS Growth %: -138.7%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
SFBC, KSBI, PVBK, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orion Marine Group (ORN) Tops Q3 EPS by 3c ; Offers Guidance
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- Ks Bancorp, Inc. (KSBI) Tops Q3 EPS by 258c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
